Altimmune, Inc

Contributing Author

Recent Articles by Altimmune, Inc

Mar-05	Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates ALT -17.92% GlobeNewswire
Mar-02	Altimmune to Participate in Upcoming Investor Conferences ALT GlobeNewswire
Feb-26	Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 ALT GlobeNewswire
Jan-29	Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock ALT +9.80% ALT GlobeNewswire
Jan-27	Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock ALT -17.15% GlobeNewswire
Jan-05	Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH ALT +16.52% GlobeNewswire
Dec-19	Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial ALT -22.77% GlobeNewswire
Dec-01	Altimmune Announces CEO Transition and Succession Plan ALT -6.27% GlobeNewswire
Nov-26	Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference ALT GlobeNewswire
Nov-11	Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting 2025 ALT GlobeNewswire
Nov-07	Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting 2025 ALT GlobeNewswire
Nov-06	Altimmune Announces Third Quarter 2025 Financial Results and Business Updates ALT +5.07% GlobeNewswire
Nov-05	Altimmune to Participate in Two Upcoming Investor Conferences ALT GlobeNewswire
Nov-03	Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder ALT GlobeNewswire
Oct-30	Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 ALT GlobeNewswire
Oct-20	Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting 2025 ALT GlobeNewswire
Sep-29	Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide ALT -5.25% GlobeNewswire
Sep-23	Altimmune to Participate in Two Upcoming Investor Conferences ALT GlobeNewswire
Sep-15	Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer ALT GlobeNewswire
Aug-26	Altimmune to Participate in Upcoming Investor Conferences ALT GlobeNewswire
Aug-19	Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) ALT GlobeNewswire
Aug-12	Altimmune Announces Second Quarter 2025 Financial Results and Business Update ALT +7.10% GlobeNewswire
Aug-11	Altimmune Board of Directors Appoints Jerry Durso as Chairman ALT GlobeNewswire
Aug-05	Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 ALT GlobeNewswire
Jul-09	Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) ALT GlobeNewswire
Jun-26	Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH ALT -53.18% GlobeNewswire
Jun-25	Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 ALT +7.23% GlobeNewswire
Jun-13	Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions ALT GlobeNewswire
May-19	Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) ALT GlobeNewswire
May-14	Altimmune to Participate at Two Upcoming Investor Conferences ALT GlobeNewswire
May-13	Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital ALT GlobeNewswire
May-13	Altimmune Announces First Quarter 2025 Financial Results and Business Update ALT GlobeNewswire
May-08	Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress ALT +8.21% GlobeNewswire
May-06	Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 ALT -7.37% GlobeNewswire

Altimmune, Inc

Recent Articles by Altimmune, Inc

Upgrade your FINVIZ experience